SYAB Stock Overview
SYNLAB AG provides clinical laboratory and medical diagnostic services for insurance companies, hospitals, pharmacies, national health organizations, practicing doctors, clinics, patients, governments, and corporations primarily in Europe.
Price History & Performance
|Historical stock prices|
|Current Share Price||€16.69|
|52 Week High||€24.60|
|52 Week Low||€13.80|
|1 Month Change||-4.63%|
|3 Month Change||2.02%|
|1 Year Change||-7.79%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-15.39%|
Recent News & Updates
SYNLAB AG (FRA:SYAB) Stock Catapults 27% Though Its Price And Business Still Lag The Market
SYNLAB AG ( FRA:SYAB ) shares have had a really impressive month, gaining 27% after a shaky period beforehand. But the...
SYNLAB (FRA:SYAB) Is Investing Its Capital With Increasing Efficiency
There are a few key trends to look for if we want to identify the next multi-bagger. Typically, we'll want to notice a...
|SYAB||DE Healthcare||DE Market|
Return vs Industry: SYAB exceeded the German Healthcare industry which returned -30.3% over the past year.
Return vs Market: SYAB exceeded the German Market which returned -23% over the past year.
|SYAB Average Weekly Movement||6.1%|
|Healthcare Industry Average Movement||3.9%|
|Market Average Movement||5.6%|
|10% most volatile stocks in DE Market||9.8%|
|10% least volatile stocks in DE Market||2.9%|
Stable Share Price: SYAB is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: SYAB's weekly volatility (6%) has been stable over the past year.
About the Company
SYNLAB AG provides clinical laboratory and medical diagnostic services for insurance companies, hospitals, pharmacies, national health organizations, practicing doctors, clinics, patients, governments, and corporations primarily in Europe. The company offers Coronavirus tests, and medical and veterinary diagnostics services. It operates through approximately 500 laboratories and 1,800 blood collection points in 36 countries in four continents.
SYNLAB Fundamentals Summary
|SYAB fundamental statistics|
Is SYAB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SYAB income statement (TTM)|
|Cost of Revenue||€954.95m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 11, 2022
|Earnings per share (EPS)||2.94|
|Net Profit Margin||16.80%|
How did SYAB perform over the long term?See historical performance and comparison
2.0%Current Dividend Yield
Is SYAB undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SYAB?
Other financial metrics that can be useful for relative valuation.
|What is SYAB's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does SYAB's PE Ratio compare to its peers?
|SYAB PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
Price-To-Earnings vs Peers: SYAB is good value based on its Price-To-Earnings Ratio (5.7x) compared to the peer average (22.6x).
Price to Earnings Ratio vs Industry
How does SYAB's PE Ratio compare vs other companies in the Healthcare Industry?
Price-To-Earnings vs Industry: SYAB is good value based on its Price-To-Earnings Ratio (5.7x) compared to the German Healthcare industry average (15.4x)
Price to Earnings Ratio vs Fair Ratio
What is SYAB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||5.7x|
|Fair PE Ratio||13.4x|
Price-To-Earnings vs Fair Ratio: SYAB is good value based on its Price-To-Earnings Ratio (5.7x) compared to the estimated Fair Price-To-Earnings Ratio (13.4x).
Share Price vs Fair Value
What is the Fair Price of SYAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SYAB (€16.69) is trading below our estimate of fair value (€33.42)
Significantly Below Fair Value: SYAB is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: SYAB's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Discover undervalued companies
How is SYNLAB forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SYAB's earnings are forecast to decline over the next 3 years (-11.8% per year).
Earnings vs Market: SYAB's earnings are forecast to decline over the next 3 years (-11.8% per year).
High Growth Earnings: SYAB's earnings are forecast to decline over the next 3 years.
Revenue vs Market: SYAB's revenue is expected to decline over the next 3 years (-0.2% per year).
High Growth Revenue: SYAB's revenue is forecast to decline over the next 3 years (-0.2% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SYAB's Return on Equity is forecast to be low in 3 years time (9.2%).
Discover growth companies
How has SYNLAB performed over the past 5 years?
Past Performance Score6/6
Past Performance Score 6/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SYAB has high quality earnings.
Growing Profit Margin: SYAB's current net profit margins (16.8%) are higher than last year (7.3%).
Past Earnings Growth Analysis
Earnings Trend: SYAB has become profitable over the past 5 years, growing earnings by 63.5% per year.
Accelerating Growth: SYAB's earnings growth over the past year (190.1%) exceeds its 5-year average (63.5% per year).
Earnings vs Industry: SYAB earnings growth over the past year (190.1%) exceeded the Healthcare industry 44.5%.
Return on Equity
High ROE: SYAB's Return on Equity (26.3%) is considered high.
Discover strong past performing companies
How is SYNLAB's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: SYAB's short term assets (€1.6B) exceed its short term liabilities (€1.1B).
Long Term Liabilities: SYAB's short term assets (€1.6B) do not cover its long term liabilities (€2.2B).
Debt to Equity History and Analysis
Debt Level: SYAB's net debt to equity ratio (35.4%) is considered satisfactory.
Reducing Debt: SYAB's debt to equity ratio has reduced from 19359.5% to 57.1% over the past 5 years.
Debt Coverage: SYAB's debt is well covered by operating cash flow (70.3%).
Interest Coverage: SYAB's interest payments on its debt are well covered by EBIT (9.9x coverage).
Discover healthy companies
What is SYNLAB current dividend yield, its reliability and sustainability?
Dividend Score 3/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: SYAB's dividend (1.98%) is higher than the bottom 25% of dividend payers in the German market (1.47%).
High Dividend: SYAB's dividend (1.98%) is low compared to the top 25% of dividend payers in the German market (4.57%).
Stability and Growth of Payments
Stable Dividend: Too early to tell whether SYAB's dividend payments have been stable as they only just started paying a dividend.
Growing Dividend: Too early to tell if SYAB's dividend payments are increasing as they only just started paying a dividend.
Earnings Payout to Shareholders
Earnings Coverage: With its low payout ratio (10.9%), SYAB's dividend payments are thoroughly covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its low cash payout ratio (8.6%), SYAB's dividend payments are thoroughly covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mathieu Floreani (53 yo)
Mr. Mathieu Floreani serves as Chief Executive Officer at Synlab Limited since April 2018 and also serves as its Chairperson of the Management Board since 2021. Mr. Floreani has served as a Director of SYN...
Experienced Board: SYAB's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
SYNLAB AG's employee growth, exchange listings and data sources
- Name: SYNLAB AG
- Ticker: SYAB
- Exchange: DB
- Founded: 1998
- Industry: Health Care Services
- Sector: Healthcare
- Implied Market Cap: €3.709b
- Shares outstanding: 222.22m
- Website: https://www.synlab.com
Number of Employees
- SYNLAB AG
- Moosacher Straße 88
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/24 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.